Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective

American Journal of Cardiology

Volumn 78, Issue 3 A, 1996, Pages 35-40

  Tcheng, James E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ADJUVANT THERAPY; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK BENEFIT ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0029798675     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00490-0     Document Type: Conference Paper

References (27)

1. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-108.
2. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. New York: Raven Press, 1992:219-273.
3. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831-843.
4. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987;48:549-554.
5. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994;308:159-168.
6. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
7. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld JW Jr. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134.
8. Lembo NJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas JS Jr, King SB III. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422-426.
9. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986;231:1559-1562.
10. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IlIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991;17(suppl B):89B-95B.
11. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
12. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal F(ab) antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995;32:1271-1281.
13. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
14. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
15. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf, for the EPIC Investigtors. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
16. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KN, Lee KL, Willerson JT, for the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886.
17. Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986;103:451-456.
18. Tcheng JE, Lincoff AM, Sigmon KN, Kitt MM, Califf RM, Topol EJ, for the IMPACT II Investigators. Platelet glycoprotein IIb/IIIa inhibition with Integrilin during percutaneous coronary intervention: the IMPACT II Trial. Circulation 1995;92(suppl I):I-543.
19. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Califf RM, Topol EJ for the IMPACT investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 195;91:2151-2157.
20. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227.
21. King SB III, et al. Administration of Tirofiban (MK-0383) will reduce the incidence of adverse cardiac outcome following PTCA/DCA (RESTORE). J Am Coll Cardiol 1996;27(suppl A):xxi.
22. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88(part 1):1512-1517.
23. Egbertson MS, Chang CT, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ Jr, Lynch RJ, Manno PD, et al. Non-peptide flbrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37:2537-2551.
24. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19:125-134.
25. Charo IF, Bekeart LS, Phillips DR. Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 1987;262:9935-9938.
26. Matsuno H, Stassen JM, Vermylen J, Deckmhn H. Inhibition of integrin function by a cyclic RDG-containing peptide prevents neointima formation. Circulation 1994;90:2203-2206.
27. Lincoff AM, et al. Results of the interim analysis of the EPILOG trial. J Am Coll Cardiol 1996;27(suppl A):xxi.